A new imaging scan to better detect and track liver cancer

This trial is testing whether adding a specialized imaging scan called F18-Piflufolastat PET/CT to standard cancer imaging (CT or MRI) can help doctors better understand and manage hepatocellular carcinoma, the most common type of liver cancer. The new scan uses a radioactive tracer that targets a protein often found on cancer cells, which may help doctors see cancer more clearly than standard imaging alone. Researchers want to know if this medication helps doctors diagnose uncertain findings, better understand how far cancer has spread, and assess whether previous treatments are working.

Standard imaging tests like CT and MRI have limitations—they sometimes cannot clearly identify whether liver spots are cancer or benign, may miss cancer spread to other areas, and can make it hard to tell if cancer is still active after treatment. This trial aims to see if the new imaging scan fills these gaps and helps doctors make better decisions about your care.